## Hepatic decompensating events in patients with type 2 diabetes, with and without MASLD/MASH/liver fibrosis and cirrhosis (Comparison between propensity-score matched cohorts)

	Exposure	Comparison	# of cases (overall risk)	# of cases (overall risk)		
Cohort size	cohort	cohort	(Exposure cohort)	(Comparison cohort)		HR (95% CI)
	no MASLD/MASH/Liver fibrosis and cirrho	osis				
42,703	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	160 (0.38%)	1,212 (2.84%)	<del></del>	0.13 (0.11–0.15)
42,809	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	901 (2.11%)	1,011 (2.36%)	l <del>=</del>	0.91 (0.84–1.00)
95,667	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	1,581 (1.65%)	2,272 (2.38%)	I <del>■</del> I	0.64 (0.60–0.68)
49,132	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	822 (1.67%)	931 (1.90%)	⊦ <del>=</del> +	0.84 (0.76–0.92)
86,301	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	1,450 (1.68%)	2,090 (2.42%)	<del>l≡l</del>	0.65 (0.61–0.70)
59,082	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	967 (1.64%)	1,191 (2.02%)	H <del>≡</del> H	0.77 (0.71–0.84)
	MASLD/MASH					
3,505	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	100 (2.85%)	305 (8.70%)	<del></del>	0.31 (0.25–0.39)
2,825	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	281 (9.95%)	324 (11.47%)	<b>⊢</b> ■	0.86 (0.74–1.01)
6,167	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	505 (8.19%)	620 (10.05%)	H■H	0.76 (0.68–0.85)
3,388	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	305 (9.00%)	340 (10.04%)	<b>⊢</b> ■-	0.87 (0.75–1.02)
6,182	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	493 (7.98%)	612 (9.90%)	<del>⊢■</del> ⊣	0.76 (0.67–0.85)
2,908	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	228 (7.84%)	226 (7.77%)	<b>⊢</b>	0.96 (0.79–1.15)
	liver fibrosis and cirrhosis					
492	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	95 (19.31%)	194 (39.43%)	— <del>■</del>	0.43 (0.34–0.55)
1,035	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	394 (38.07%)	433 (41.84%)	<b>⊢=</b> -	0.87 (0.76–0.99)
1,641	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	601 (36.62%)	683 (41.62%)	⊦ <del>≡</del> ⊣	0.81 (0.73–0.90)
958	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	388 (40.50%)	393 (41.02%)	H	0.96 (0.83–1.11)
1,597	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	579 (36.26%)	667 (41.77%)	H■H	0.79 (0.71–0.88)
865	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	324 (37.46%)	300 (34.68%)	H=-1	1.03 (0.88–1.21)
					0.20 0.30 0.500.70 1.0 Hazard Ratio (HR)	2.0 3.004.0